Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Sexually Transmitted Diseases

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 102 articles: HTML format

Single Articles

April 2024
1. DOWNHAM L, Rol ML, Forestier M, Romero P, et al
   Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
   Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34953.
   PubMed     Abstract available
   
   
   
2. SINGINI MG, Muchengeti M, Sitas F, Chen WC, et al
   Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
   Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34919.
   PubMed     Abstract available
   
   
   March 2024
3. PORTNOY A, Pedersen K, Sy S, Trope A, et al
   Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
   Int J Cancer. 2024;154:1073-1081.
   PubMed     Abstract available
   
   
   
4. OLTHOF EMG, Aitken CA, Siebers AG, van Kemenade FJ, et al
   The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
   Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34902.
   PubMed     Abstract available
   
   
   
5. LU Y, Clifford GM, Fairley CK, Grulich AE, et al
   Human papillomavirus and p16(INK4a) in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis.
   Int J Cancer. 2024;154:830-841.
   PubMed     Abstract available
   
   
   February 2024
6. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
   The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
   Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
   PubMed     Abstract available
   
   
   
7. WEN TM, Xu XQ, Zhao XL, Pan CH, et al
   Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.
   Int J Cancer. 2024 Feb 17. doi: 10.1002/ijc.34882.
   PubMed     Abstract available
   
   
   January 2024
8. STIER EA, Clarke MA, Deshmukh AA, Wentzensen N, et al
   International Anal Neoplasia Society's consensus guidelines for anal cancer screening.
   Int J Cancer. 2024 Jan 31. doi: 10.1002/ijc.34850.
   PubMed     Abstract available
   
   
   November 2023
9. 
   Correction to "A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers".
   Int J Cancer. 2023 Nov 19. doi: 10.1002/ijc.34789.
   PubMed    
   
   
   
10. BONI SP, Tenet V, Horo A, Heideman DAM, et al
    High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020.
    Int J Cancer. 2023 Nov 9. doi: 10.1002/ijc.34774.
    PubMed     Abstract available
    
    
    October 2023
11. COCUZZA CE, Dhillon SK, Martinelli M, Giubbi C, et al
    Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34754.
    PubMed     Abstract available
    
    
    September 2023
12. INTURRISI F, de Sanjose S, Desai KT, Dagnall C, et al
    A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
    Int J Cancer. 2023 Sep 29. doi: 10.1002/ijc.34698.
    PubMed     Abstract available
    
    
    
13. LEHTINEN M, Butt J, Gray P, Brenner N, et al
    HPV16 E6-antibody associated risk of oropharyngeal cancer increases by calendar-time: A nested case-control study.
    Int J Cancer. 2023;153:1313-1315.
    PubMed    
    
    
    
14. KUSTERS JMA, Diergaarde B, Ness A, Schim van der Loeff MF, et al
    Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex.
    Int J Cancer. 2023 Sep 11. doi: 10.1002/ijc.34710.
    PubMed     Abstract available
    
    
    
15. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    PubMed     Abstract available
    
    
    August 2023
16. WHITE C, Reynolds S, Murphy K, Keegan H, et al
    Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland.
    Int J Cancer. 2023 Aug 26. doi: 10.1002/ijc.34685.
    PubMed     Abstract available
    
    
    
17. VOSS FO, Thuijs NB, Duin S, Ozer M, et al
    Clinical validation of methylation biomarkers for optimal detection of high-grade vulvar intraepithelial neoplasia.
    Int J Cancer. 2023;153:783-791.
    PubMed     Abstract available
    
    
    July 2023
18. KIM MN, Han K, Yoo J, Hwang SG, et al
    Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
    Int J Cancer. 2023 Jul 13. doi: 10.1002/ijc.34637.
    PubMed     Abstract available
    
    
    
19. CLARKE MA, Wentzensen N
    Response to comments on: "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 Jul 4. doi: 10.1002/ijc.34642.
    PubMed    
    
    
    
20. DIAS GONCALVES LIMA F, Schim van der Loeff M
    Comments on: "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 Jul 4. doi: 10.1002/ijc.34641.
    PubMed    
    
    
    
21. REBOLJ M, Sargent A, Njor SH, Cuschieri K, et al
    Widening the offer of human papillomavirus self-sampling to all women eligible for cervical screening: Make haste slowly.
    Int J Cancer. 2023;153:8-19.
    PubMed     Abstract available
    
    
    May 2023
22. 
    Erratum to "A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups".
    Int J Cancer. 2023 May 19. doi: 10.1002/ijc.34567.
    PubMed    
    
    
    March 2023
23. CUZICK J, Adcock R, Kinney W, Castle PE, et al
    Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States.
    Int J Cancer. 2023 Mar 22. doi: 10.1002/ijc.34519.
    PubMed     Abstract available
    
    
    
24. DE SOUZA MMA, Hartel G, Olsen CM, Whiteman DC, et al
    Oral HPV infection and HPV vaccination in an Australian cohort.
    Int J Cancer. 2023 Mar 21. doi: 10.1002/ijc.34517.
    PubMed     Abstract available
    
    
    
25. ALBUQUERQUE A
    Comments on "Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis": Prevention of anal squamous cell carcinoma in women: How to move forward: Prevention of anal squamous c
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34490.
    PubMed    
    
    
    
26. DONG L, Nygard M, Stoer NC, Klungsoyr O, et al
    Real-World Effectiveness of Hpv Vaccination Against Cervical Neoplasia Among Birth Cohorts Ineligible for Routine Vaccination.
    Int J Cancer. 2023 Mar 3. doi: 10.1002/ijc.34489.
    PubMed     Abstract available
    
    
    February 2023
27. HERZOG C, Vavourakis CD, Barrett JE, Karbon G, et al
    HPV-induced host epigenetic reprogramming is lost upon progression to high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2023 Feb 21. doi: 10.1002/ijc.34477.
    PubMed     Abstract available
    
    
    January 2023
28. RASMUSSEN CL, Thomsen LT, Baandrup L, Franzmann MB, et al
    Time trends in prevalence of p16 positivity and combined HPV/p16 positivity in a large cohort of Danish vulvar cancer patients.
    Int J Cancer. 2023 Jan 24. doi: 10.1002/ijc.34446.
    PubMed     Abstract available
    
    
    
29. BUDHATHOKI S, Diergaarde B, Liu G, Olshan A, et al
    A risk prediction model for head and neck cancers incorporating lifestyle factors, HPV serology and genetic markers.
    Int J Cancer. 2023 Jan 24. doi: 10.1002/ijc.34444.
    PubMed     Abstract available
    
    
    
30. SUZUKI H
    HPV hijacks enhancers to activate oncogenes in head and neck squamous cell carcinoma cells.
    Int J Cancer. 2023 Jan 24. doi: 10.1002/ijc.34440.
    PubMed    
    
    
    
31. MIMA M, Okabe A, Hoshii T, Nakagawa T, et al
    Tumorigenic activation around HPV integrated sites in head and neck squamous cell carcinoma.
    Int J Cancer. 2023 Jan 17. doi: 10.1002/ijc.34439.
    PubMed     Abstract available
    
    
    
32. CARVAJAL LJ, Shing JZ, Vanegas JC, Gonzalez E, et al
    TRENDS IN INCIDENCE RATES OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS OVERALL AND BY POTENTIAL RELATEDNESS TO HUMAN PAPILLOMAVIRUS, COSTA RICA 2006-2015.
    Int J Cancer. 2023 Jan 17. doi: 10.1002/ijc.34437.
    PubMed     Abstract available
    
    
    December 2022
33. ROBERTS JM, Machalek DA, Butler BC, Crescini J, et al
    Older women testing positive for HPV 16/18 on cervical screening and risk of high-grade cervical abnormality.
    Int J Cancer. 2022 Dec 5. doi: 10.1002/ijc.34393.
    PubMed     Abstract available
    
    
    
34. SAKAKIBARA A, Nakayama T, Uchida H, Odagiri Y, et al
    Trends and future projections of cervical cancer-related outcomes in Japan: What happens if the HPV vaccine program is not implemented?
    Int J Cancer. 2022 Dec 5. doi: 10.1002/ijc.34391.
    PubMed     Abstract available
    
    
    November 2022
35. BAENA A, Mesher D, Salgado Y, Martinez S, et al
    Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen-positive women: results from the ESTAMPA study.
    Int J Cancer. 2022 Nov 30. doi: 10.1002/ijc.34384.
    PubMed     Abstract available
    
    
    
36. GOTTSCHLICH A, Payne BA, Trawin J, Albert A, et al
    Experiences with thermal ablation for cervical pre-cancer treatment after self-collection HPV-based screening in the ASPIRE Mayuge randomized trial.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34369.
    PubMed     Abstract available
    
    
    October 2022
37. SIVARS L, Palsdottir K, Crona Guterstam Y, Falconer H, et al
    The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34333.
    PubMed     Abstract available
    
    
    
38. RING LL, Munk C, Galanakis M, Tota JE, et al
    Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019 - population impact of multi-cohort vaccination against human papillomavirus infection.
    Int J Cancer. 2022 Oct 17. doi: 10.1002/ijc.34328.
    PubMed     Abstract available
    
    
    September 2022
39. ADEBAMOWO SN, Befano B, Cheung LC, Rodriguez AC, et al
    Different human papillomavirus types share early natural history transitions in immunocompetent women.
    Int J Cancer. 2022;151:920-929.
    PubMed     Abstract available
    
    
    
40. KAHESA C, Thomsen LT, Linde DS, Mchome B, et al
    Comparison of human papillomavirus (HPV)-based cervical cancer screening strategies in Tanzania among women with and without HIV.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34283.
    PubMed     Abstract available
    
    
    
41. LEHTINEN M, Pimenoff VN, Nedjai B, Louvanto K, et al
    Assessing the risk of cervical neoplasia in the post-HPV vaccination era.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34286.
    PubMed     Abstract available
    
    
    August 2022
42. DESHMUKH AA, Damgacioglu H, Georges D, Sonawane K, et al
    Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: a worldwide analysis.
    Int J Cancer. 2022 Aug 28. doi: 10.1002/ijc.34269.
    PubMed     Abstract available
    
    
    
43. FRENSEMEIER K, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F, et al
    Dickkopf-1 expression is repressed by oncogenic human papillomaviruses (HPVs) and regulates the Cisplatin sensitivity of HPV-positive cancer cells in a JNK-dependent manner.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34250.
    PubMed     Abstract available
    
    
    
44. NORMAN I, Yilmaz E, Hjerpe A, Hortlund M, et al
    Atypical glandular cells and development of cervical cancer: Population-based cohort study.
    Int J Cancer. 2022 Aug 13. doi: 10.1002/ijc.34242.
    PubMed     Abstract available
    
    
    July 2022
45. GARGANO JW, McClung N, Lewis RM, Park IU, et al
    HPV type-specific trends in cervical precancers in the United States, 2008-2016.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34231.
    PubMed     Abstract available
    
    
    
46. JOSHI S, Muwonge R, Kulkarni V, Mandolkar M, et al
    Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India.
    Int J Cancer. 2022 Jul 19. doi: 10.1002/ijc.34221.
    PubMed     Abstract available
    
    
    
47. CLARKE MA, Deshmukh AA, Suk R, Roberts J, et al
    A Systematic Review and Meta-Analysis of Cytology and HPV-related Biomarkers for Anal Cancer Screening Among Different Risk Groups.
    Int J Cancer. 2022 Jul 6. doi: 10.1002/ijc.34199.
    PubMed     Abstract available
    
    
    June 2022
48. AUVINEN E, Nieminen P, Pellinen J, Dillner J, et al
    HPV self-sampling with mRNA testing benefits routine screening.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34170.
    PubMed     Abstract available
    
    
    
49. DESAI KT, Adepiti CA, Schiffman M, Egemen D, et al
    Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34151.
    PubMed     Abstract available
    
    
    May 2022
50. GIORGI ROSSI P, Ronco G, Mancuso P, Carozzi F, et al
    Performance of HPV E6/E7 mRNA Assay as Primary Screening Test. Results from the NTCC2 Trial.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34120.
    PubMed     Abstract available
    
    
    
51. BURGER EA, Laprise JF, Sy S, Regan MC, et al
    Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting.
    Int J Cancer. 2022 May 5. doi: 10.1002/ijc.34054.
    PubMed     Abstract available
    
    
    
52. HURTADO-SALGADO E, Cardenas-Cardenas L, Salmeron J, Luna-Gordillo R, et al
    Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level.
    Int J Cancer. 2022;150:1422-1430.
    PubMed     Abstract available
    
    
    April 2022
53. ADCOCK R, Nedjai B, Lorincz A, Scibior-Bentkowska D, et al
    DNA methylation testing with S5 for triage of high-risk HPV positive women.
    Int J Cancer. 2022 Apr 27. doi: 10.1002/ijc.34050.
    PubMed     Abstract available
    
    
    
54. ZHANG L, Zhao X, Hu S, Chen S, et al
    Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34041.
    PubMed     Abstract available
    
    
    
55. GOTTSCHLICH A, Gondara L, Smith LW, Cook D, et al
    HPV-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV FOr CervicAL Cancer (HPV FOCAL) trial.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34039.
    PubMed     Abstract available
    
    
    
56. SAHASRABUDDHE VV, Castle PE, Schiffman M, Wentzensen N, et al
    Reply to: Comments on 'Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening'.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34013.
    PubMed    
    
    
    
57. BRENTNALL AR, Rebolj M
    Comments on: "Meta-analysis of agreement/concordance statistics in studies comparing self-versus clinician-collected samples for HPV testing in cervical cancer screening".
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34014.
    PubMed    
    
    
    
58. GARSET-ZAMANI M, Carlander AF, Jakobsen KK, Friborg J, et al
    Impact of specific high-risk human papillomavirus genotypes on survival in oropharyngeal cancer.
    Int J Cancer. 2022;150:1174-1183.
    PubMed     Abstract available
    
    
    March 2022
59. RETTIG EM, Faden DL, Sandhu S, Wong K, et al
    Detection of Circulating Tumor Human Papillomavirus DNA Before Diagnosis of HPV-Positive Head and Neck Cancer.
    Int J Cancer. 2022 Mar 9. doi: 10.1002/ijc.33996.
    PubMed     Abstract available
    
    
    February 2022
60. ANTONSSON A, de Souza MMA, Panizza BJ, Whiteman DC, et al
    Sexual debut and association with oral HPV infection, persistence and oropharyngeal cancer - an analysis of two Australian cohorts.
    Int J Cancer. 2022 Feb 28. doi: 10.1002/ijc.33986.
    PubMed     Abstract available
    
    
    
61. ARBYN M, Castle PE, Schiffman M, Wentzensen N, et al
    Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening.
    Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33967.
    PubMed     Abstract available
    
    
    December 2021
62. HORTLUND M, Muhr LSA, Lagheden C, Hjerpe A, et al
    Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program.
    Int J Cancer. 2021;149:2083-2090.
    PubMed     Abstract available
    
    
    
63. REBOLJ M, Mathews CS, Pesola F, Castanon A, et al
    Acceleration of Cervical Cancer Diagnosis with Human Papillomavirus Testing Below Age 30: Observational Study.
    Int J Cancer. 2021 Dec 12. doi: 10.1002/ijc.33900.
    PubMed     Abstract available
    
    
    November 2021
64. LASSEN P, Huang SH, Su J, Waldron J, et al
    Treatment outcomes and survival following definitive (chemo) radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts.
    Int J Cancer. 2021 Nov 18. doi: 10.1002/ijc.33876.
    PubMed     Abstract available
    
    
    
65. SPENCER JC, Campos NG, Burger EA, Sy S, et al
    Potential Effectiveness of a Therapeutic HPV Intervention Campaign in Uganda.
    Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33867.
    PubMed     Abstract available
    
    
    October 2021
66. GUSTINUCCI D, Benevolo M, Cesarini E, Mancuso P, et al
    Accuracy of Different Triage Strategies for HPV Positivity in an Italian Screening Population.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33858.
    PubMed     Abstract available
    
    
    
67. PEDERSEN K, Portnoy A, Sy S, Hansen BT, et al
    Switching clinic-based cervical cancer screening programs to HPV self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
    Int J Cancer. 2021 Oct 18. doi: 10.1002/ijc.33850.
    PubMed     Abstract available
    
    
    
68. TAWK B, Wirkner U, Schwager C, Rein K, et al
    Tumor DNA-Methylome derived Epigenetic Fingerprint Identifies HPV-negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33842.
    PubMed     Abstract available
    
    
    September 2021
69. BANILA C, Lorincz AT, Scibior-Bentkowska D, Clifford GM, et al
    Clinical performance of methylation as a biomarker for cervical carcinoma-in-situ and cancer diagnosis: a worldwide study.
    Int J Cancer. 2021 Sep 25. doi: 10.1002/ijc.33815.
    PubMed     Abstract available
    
    
    
70. VERHOEF L, Bleeker MCG, Polman N, Steenbergen RDM, et al
    Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: results from a Dutch primary HPV-based screening cohort.
    Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33820.
    PubMed     Abstract available
    
    
    
71. WRIGHT TC JR, Stoler MH, Ranger-Moore J, Fang Q, et al
    Clinical Validation of p16/Ki-67 Dual-Stained Cytology Triage of HPV-Positive Women - Results from the IMPACT Trial.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33812.
    PubMed     Abstract available
    
    
    
72. TANAKA H, Suzuki M, Takemoto N, Fukusumi T, et al
    Performance of Oral HPV DNA, Oral HPV mRNA, and Circulating Tumor HPV DNA in the Detection of HPV-Related Oropharyngeal Cancer and Cancer of Unknown Primary.
    Int J Cancer. 2021 Sep 6. doi: 10.1002/ijc.33798.
    PubMed     Abstract available
    
    
    August 2021
73. KEANE A, Ng CW, Simms KT, Nguyen D, et al
    The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of HPV screening with self-collection and digital registry support.
    Int J Cancer. 2021 Aug 7. doi: 10.1002/ijc.33759.
    PubMed     Abstract available
    
    
    July 2021
74. VAN DER ZEE RP, Meijer CJLM, Cuming T, Kreuter A, et al
    Characterisation of anal intraepithelial neoplasia and anal cancer in HIV-positive men by immunohistochemical markers p16, Ki-67, HPV-E4, and DNA methylation markers.
    Int J Cancer. 2021 Jul 26. doi: 10.1002/ijc.33748.
    PubMed     Abstract available
    
    
    
75. NAUTA IH, Heideman DAM, Brink A, van der Steen B, et al
    The unveiled reality of human papillomavirus as risk factor for oral cavity squamous cell carcinoma.
    Int J Cancer. 2021;149:420-430.
    PubMed     Abstract available
    
    
    June 2021
76. VAN SCHALKWYK C, Moodley J, Welte A, Johnson LF, et al
    Modelling the impact of prevention strategies on cervical cancer incidence in South Africa.
    Int J Cancer. 2021 Jun 24. doi: 10.1002/ijc.33716.
    PubMed     Abstract available
    
    
    
77. JAYARAJ R, Shaw P, Kumarasamy C, Shetty SS, et al
    Comments on "Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis".
    Int J Cancer. 2021;148:2857-2858.
    PubMed    
    
    
    
78. MALAGON T, Volesky KD, Franco EL
    Reply to: Comments on cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
    Int J Cancer. 2021;148:2859-2860.
    PubMed    
    
    
    May 2021
79. ARROYO MUHR LS, Hultin E, Dillner J
    Transcription of Human Papillomaviruses in Non-Melanoma Skin Cancers of the Immunosuppressed.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33683.
    PubMed     Abstract available
    
    
    
80. TORRES-IBARRA L, Lorincz AT, Wheeler CM, Cuzick J, et al
    Adjunctive testing by cytology, p16/Ki-67 dual-stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen-positive women.
    Int J Cancer. 2021;148:2264-2273.
    PubMed     Abstract available
    
    
    April 2021
81. GREEN LI, Mathews CS, Waller J, Kitchener H, et al
    Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing.
    Int J Cancer. 2021;148:1850-1857.
    PubMed     Abstract available
    
    
    
82. HOPPE-SEYLER K, Herrmann AL, Daschle A, Kuhn BJ, et al
    Effects of Metformin on the virus/host cell crosstalk in HPV-positive cancer cells.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33594.
    PubMed    
    
    
    
83. LI N, Hu Y, Zhang X, Liu Y, et al
    DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population.
    Int J Cancer. 2021;148:1768-1777.
    PubMed     Abstract available
    
    
    March 2021
84. VINK FJ, Dick S, Heideman DAM, De Strooper LMA, et al
    Classification of high-grade CIN by p16(ink4a) , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33566.
    PubMed     Abstract available
    
    
    February 2021
85. DONKEN R, van Niekerk D, Hamm J, Spinelli JJ, et al
    Declining Rates of Cervical Intraepithelial Neoplasia in British Columbia, Canada: An Ecological Analysis On The Effects of The School-Based HPV Vaccination Program.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33513.
    PubMed    
    
    
    
86. TEKA B, Gizaw M, Ruddies F, Addissie A, et al
    Population-based human papillomavirus infection and genotype distribution among women in rural areas of South Central Ethiopia.
    Int J Cancer. 2021;148:723-730.
    PubMed     Abstract available
    
    
    
87. HUANG HJ, Tung HJ, Yang LY, Chao A, et al
    Role of human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2021;148:665-672.
    PubMed     Abstract available
    
    
    January 2021
88. AARNIO R, Isacson I, Sanner K, Gustavsson I, et al
    Comparison of vaginal self-sampling and cervical sampling by medical professionals for the detection of HPV and CIN2+: a randomized study.
    Int J Cancer. 2021 Jan 26. doi: 10.1002/ijc.33482.
    PubMed     Abstract available
    
    
    
89. BEYRANVAND NEJAD E, Labrie C, van der Sluis TC, van Duikeren S, et al
    Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function.
    Int J Cancer. 2021;148:211-225.
    PubMed     Abstract available
    
    
    December 2020
90. ANTONSSON A, de Souza M, Wood ZC, Carroll A, et al
    Natural history of oral HPV infection - longitudinal analyses in prospective cohorts from Australia.
    Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33442.
    PubMed     Abstract available
    
    
    November 2020
91. MALAGON T, Volesky KD, Bouten S, Laprise C, et al
    Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
    Int J Cancer. 2020;147:2695-2707.
    PubMed     Abstract available
    
    
    
92. BIZZARRI N, Anchora LP, Cattani P, De Vincenzo R, et al
    Peritoneal Hpv-Dna Test In Cervical Cancer (Pioneer Study): A Proof Of Concept.
    Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33380.
    PubMed     Abstract available
    
    
    October 2020
93. REINHOLDT K, Thomsen LT, Munk C, Dehlendorff C, et al
    Incidence of HPV-related anogenital precancer and cancer in women with diabetes - a nationwide registry-based cohort study.
    Int J Cancer. 2020 Oct 31. doi: 10.1002/ijc.33365.
    PubMed     Abstract available
    
    
    
94. REZHAKE R, Chen F, Hu SY, Zhao XL, et al
    Triage options to manage high-risk human papillomavirus-positive women: A population-based cross-sectional study from rural China.
    Int J Cancer. 2020;147:2053-2064.
    PubMed     Abstract available
    
    
    
95. RAMIREZ AT, Sanchez GI, Nedjai B, Agudelo MC, et al
    Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33314.
    PubMed     Abstract available
    
    
    September 2020
96. BONDE J, Floore A, Ejegod D, Vink FJ, et al
    Methylation markers FAM19A4 and miR124-2 as triage strategy for primary HPV screen positive women; A large European multi-center study.
    Int J Cancer. 2020 Sep 30. doi: 10.1002/ijc.33320.
    PubMed     Abstract available
    
    
    
97. PLATH M, Gass J, Hlevnjak M, Li Q, et al
    Unraveling most abundant mutational signatures in head and neck cancer.
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33297.
    PubMed     Abstract available
    
    
    July 2020
98. ARBYN M, Gultekin M, Morice P, Nieminen P, et al
    The European response to the WHO call to eliminate cervical cancer as a public health problem.
    Int J Cancer. 2020 Jul 7. doi: 10.1002/ijc.33189.
    PubMed     Abstract available
    
    
    June 2020
99. GALATI L, Combes JD, Gupta P, Sen R, et al
    Detection of a large spectrum of viral infections in conjunctival pre-malignant and malignant lesions.
    Int J Cancer. 2020 Jun 11. doi: 10.1002/ijc.33149.
    PubMed     Abstract available
    
    
    December 2019
100. GABY S, Eva E, Andreas W, Wilhelm O, et al
     Reducing Overtreatment Associated with Overdiagnosis in Cervical Cancer Screening - A Model-based Benefit-Harm Analysis for Austria.
     Int J Cancer. 2019 Dec 24. doi: 10.1002/ijc.32849.
     PubMed     Abstract available
     
     
     November 2019
101. COMBES JD, Clifford GM, Gunthard HF, Hauser C, et al
     Antibodies against HPV16E6 oncoprotein in the Swiss HIV Cohort Study: kinetics and anal cancer risk prediction.
     Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32784.
     PubMed     Abstract available
     
     
     August 2019
102. VINK FJ, Meijer CJLM, Clifford GM, Poljak M, et al
     FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.
     Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Sexually Transmitted Diseases is free of charge.